The Prostate Cancer Foundation (PCF) is inviting Letters of Intent for the 2025 TACTICAL Awards (Therapy ACceleration To Intercept CAncer Lethality). These grants support high-risk, high-reward projects focused on developing next-generation therapies for lethal prostate cancer. International academic teams are encouraged to apply.
Eligibility Criteria
-
Teams must include at least five investigators from a minimum of four nonprofit academic institutions.
-
At least two investigators must be early-career researchers (within six years of their terminal degree).
-
Young investigators must not have received more than 2 million US Dollars in direct research funding.
-
For-profit and government institution researchers are not eligible.
-
Multidisciplinary, diverse, and inclusive team structures are favored.
-
Only academic institutions are eligible to receive funds.
Funding Details
-
Grant amount: 5 million to 10 million US Dollars per award
-
Duration: 3 to 5 years
-
Institutional indirect costs capped at 10%
-
Clinical trial costs are not eligible, but correlative studies linked to trials are encouraged
Research Topics of Interest
-
Theranostics
-
Novel therapeutics for undruggable targets
-
Precision biotechnology innovation
-
First-in-field immunotherapies for prostate cancer
-
Artificial intelligence and machine learning in oncology
-
Host microbiome and tumor metabolism interactions
Key Deadlines
-
Letter of Intent (LOI) due: May 19, 2025
-
Notification to submit full application: May 28, 2025
-
Full application deadline: July 9, 2025 at 3:00 p.m. EDT
Where to Apply
-
Submit LOI by email: [email protected]
-
Submit full applications (by invitation only): https://pcf.smartsimple.com
-
Additional information: https://pcf.org/open-rfas